文献速递消化系统肿瘤

替雷利珠单抗对比索拉非尼一线治疗不可切除肝细胞癌:一项3期随机临床试验

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

RATIONALE-301研究为开放标签、全球多区域3期随机试验,纳入674例不可切除肝细胞癌患者,比较替雷利珠单抗与索拉非尼一线治疗。结果显示,替雷利珠单抗总生存非劣效于索拉非尼(中位15.9个月 vs 14.1个月,HR 0.85),但未达优效;客观缓解率更高(14.3% vs 5.4%),缓解持续时间更长(36.1个月 vs 11.0个月),无进展生存期索拉非尼更长(2.1个月 vs 3.4个月),替雷利珠单抗安全性更优。

要点

  • 替雷利珠单抗一线治疗不可切除肝细胞癌的总生存非劣效于索拉非尼(中位15.9 vs 14.1个月,HR 0.85)。
  • 替雷利珠单抗客观缓解率14.3% vs 索拉非尼5.4%,中位缓解持续时间36.1 vs 11.0个月。
  • ≥3级治疗相关不良事件替雷利珠单抗22.2% vs 索拉非尼53.4%。

核心结论

  • 在RATIONALE-301中,替雷利珠单抗相比索拉非尼显示出非劣效的总生存获益,客观缓解率更高且缓解更持久,中位无进展生存期索拉非尼更长,替雷利珠单抗安全性更优。

研究设计与样本

  • 开放标签、全球多区域3期RATIONALE-301随机临床试验,2017年12月27日至2019年10月2日入组,数据截止2022年7月11日。
  • 纳入组织学确诊的肝细胞癌、巴塞罗那临床肝癌分期B或C期、局部区域治疗后进展或不适合局部区域治疗、ECOG体力状态评分≤1、Child-Pugh A级的系统治疗初治成人患者,1:1随机接受替雷利珠单抗200 mg静脉每3周一次或索拉非尼甲苯磺酸盐400 mg口服每日两次。
  • 共674例患者纳入分析(570例男性[84.6%];中位年龄61岁[范围23-86岁]),截至2022年7月11日最短随访33个月。

主要发现

  • 在意向治疗人群(n=674)中,替雷利珠单抗组中位总生存15.9个月(95%CI 13.2-19.7)vs 索拉非尼组14.1个月(95%CI 12.6-17.4),HR 0.85(95.003%CI 0.71-1.02),达到非劣效但未达优效。
  • 替雷利珠单抗组客观缓解率14.3%(n=49)vs 索拉非尼组5.4%(n=18),中位缓解持续时间36.1个月(95%CI 16.8至不可评估)vs 11.0个月(95%CI 6.2-14.7)。
  • 替雷利珠单抗组中位无进展生存期2.1个月(95%CI 2.1-3.5)vs 索拉非尼组3.4个月(95%CI 2.2-4.1),HR 1.11(95%CI 0.92-1.33)。
  • 治疗中出现的不良事件发生率替雷利珠单抗组96.2%(325/338)vs 索拉非尼组100%(n=324);≥3级治疗相关不良事件替雷利珠单抗组75例(22.2%)vs 索拉非尼组173例(53.4%)。
  • 导致停药的治疗相关不良事件替雷利珠单抗组21例(6.2%)vs 索拉非尼组33例(10.2%),导致药物调整的治疗相关不良事件68例(20.1%)vs 187例(57.7%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and additional first-line treatments are needed. The programmed cell death protein 1 inhibitor tislelizumab demonstrated efficacy and a tolerable safety profile as second-line HCC treatment. OBJECTIVE: To investigate efficacy and safety of tislelizumab vs sorafenib tosylate for first-line treatment of unresectable HCC. DESIGN, SETTING, AND PARTICIPANTS: The open-label, global, multiregional phase 3 RATIONALE-301 randomized clinical trial enrolled systemic therapy-naive adults with histologically confirmed HCC, Barcelona Clinic Liver Cancer stage B or C disease, disease progression following (or patient was not amenable to) locoregional therapy, Eastern Cooperative Oncology Group performance status of 1 or less, and Child-Pugh class A, between December 27, 2017, and October 2, 2019. Data cutoff was July 11, 2022. INTERVENTION: Patients were randomized 1:1 to receive tislelizumab, 200 mg intravenously every 3 weeks, or sorafenib tosylate, 400 mg orally twice daily. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS); secondary end points included objective response rate, progression-free survival, duration of response, and safety. RESULTS: A total of 674 patients were included in the analysis (570 men [84.6%]; median age, 61 years [range, 23-86 years]). As of July 11, 2022, minimum study follow-up was 33 months. The primary end point of OS noninferiority of tislelizumab vs sorafenib was met in the intention-to-treat population (n = 674); median overall survival was 15.9 (95% CI, 13.2-19.7) months vs 14.1 (95% CI, 12.6-17.4) months, respectively (hazard ratio [HR], 0.85 [95.003% CI, 0.71-1.02]), and superiority of tislelizumab vs sorafenib was not met. The objective response rate was 14.3% (n = 49) for tislelizumab vs 5.4% (n = 18) for sorafenib, and median duration of response was 36.1 (95% CI, 16.8 to not evaluable) months vs 11.0 (95% CI, 6.2-14.7) months, respectively. Median progression-free survival was 2.1 (95% CI, 2.1-3.5) months vs 3.4 (95% CI, 2.2-4.1) months with tislelizumab vs sorafenib (HR, 1.11 [95% CI, 0.92-1.33]). The incidence of treatment-emergent adverse events (AEs) was 96.2% (325 of 338 patients) for tislelizumab and 100% (n = 324) for sorafenib. Grade 3 or greater treatment-related AEs were reported in 75 patients (22.2%) receiving tislelizumab and 173 (53.4%) receiving sorafenib. There was a lower incidence of treatment-related AEs leading to drug discontinuation (21 [6.2%] vs 33 [10.2%]) and drug modification (68 [20.1%] vs 187 [57.7%]) with tislelizumab vs sorafenib. CONCLUSIONS AND RELEVANCE: In RATIONALE-301, tislelizumab demonstrated OS benefit that was noninferior vs sorafenib, with a higher objective response rate and more durable responses, while median progression-free survival was longer with sorafenib. Tislelizumab demonstrated a favorable safety profile vs sorafenib. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03412773.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37796513. doi:10.1001/jamaoncol.2023.4003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。